Stoke Therapeutics, Inc. (0GT.F)
| Previous Close | 10.70 |
| Open | 10.80 |
| Bid | 11.20 x N/A |
| Ask | 11.40 x N/A |
| Day's Range | 10.80 - 10.80 |
| 52 Week Range | 3.16 - 13.00 |
| Volume | |
| Avg. Volume | 20 |
| Market Cap | 602.907M |
| Beta (5Y Monthly) | 0.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.22 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 62.88 |
ZacksEarnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireStoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
BEDFORD, Mass., April 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke’s leadership te
Business WireStoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass., April 04, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a.m. ET.
